Yifan Pharmaceutical Co., Ltd. (SZSE:002019) agreed to acquire 19.79% stake in BIOTON S.A. (WSE:BIO) from Ningbo Free Trade Zone Dongren Investment Co., Ltd. for approximately CNY 450 million on August 30, 2019. The deal value will be payable in cash. In a related transaction, Yifan Pharmaceutical Co., Ltd. signed an agreement to acquire 11.86% stake in BIOTON S.A. from Kelipond Investment Limited for approximately CNY 270 million on August 30, 2019. The acquisition funds will be arrange from the Yifan Pharmaceutical's own funds or self-financed funds. The Yifan Pharmaceutical's seventh directorate in its fifth special meeting has already approved the deal. It does not need approval from the Yifan Pharmaceutical's shareholders. This transaction matter still needs to fulfill approval, registration, or filing record procedure with the National Development and Reform Commission, Ministry of Commerce, State Administration of Foreign Exchange and relevant departments. The matter does not need any special approval or waiver from the Polish Government or from Warsaw Stock Exchange.

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) completed the acquisition of 19.79% stake in BIOTON S.A. (WSE:BIO) from Ningbo Free Trade Zone Dongren Investment Co., Ltd. on October 30, 2019.